NeoGraph Analytics
BiotechnologyNorth America2023 – 2032

Global United States Precision Medicine Market Size, Share and Trends Analysis

United States Precision Medicine market size was $38.5B in 2023, forecast to hit $87.2B by 2032, growing at a 9.5% CAGR.

Revenue, 2023

$38.5B

Forecast, 2032

$87.1B

CAGR, 2024-2032

9.5%

Report Coverage

North America

Code: united-states-precision-medicine-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

The United States precision medicine market was valued at approximately $38.5 billion in 2023 and is projected to reach $87.2 billion by 2032, growing at a CAGR of 9.5%. Dominated by oncology applications and NGS-based diagnostics, the market benefits from strong FDA regulatory support, rising R&D investments, and increasing adoption of AI-driven genomic profiling across hospitals, diagnostic laboratories, and pharmaceutical companies nationwide.

02

Key Highlights

1

US precision medicine market driven by oncology applications, genomic sequencing advances, and rising personalized therapy adoption across hospitals and diagnostic labs.

2

NGS and bioinformatics platforms dominate technology segmentation, enabling faster and more cost-effective genomic profiling for targeted treatments.

3

FDA's expanding companion diagnostics approvals and AI-driven drug discovery are accelerating market growth and clinical integration of precision therapies.

03

Market Overview

Market Context

The US precision medicine market is experiencing rapid transformation driven by declining genomic sequencing costs, expanding biomarker discovery, and increasing clinical adoption of targeted therapies across oncology, cardiology, and rare disease domains.

The US precision medicine market, valued at $38.5B in 2023, is experiencing high growth driven by genomic sequencing, companion diagnostics, and targeted therapies. Oncology leads application segments at 45% share, while NGS technology dominates the landscape.

Market Stage

High growth

Adoption Level

Growing

Key Trends

Rapid adoption of next-generation sequencing in clinical diagnosticsIncreasing FDA approvals for companion diagnostics and targeted therapiesAI and machine learning integration in genomic data analysisGrowing investments in liquid biopsy and multi-omics platforms
04

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 9.5%

Base Year (2023)

$38.5B

Forecast (2032)

$87.1B

CAGR (2024-2032)

9.5%

Market size by year, 2024-2032, in USD Billion.
YearMarket size ($ Billion)
2023Base year$38.50B
2024$42.16B
2025$46.16B
2026$50.55B
2027$55.35B
2028$60.61B
2029$66.37B
2030$72.67B
2031$79.57B
2032$87.13B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Forecast Analysis

With a 9.5% CAGR, the US market is projected to nearly double from $38.5B to $87.2B by 2032, fueled by liquid biopsy adoption, AI-enhanced diagnostics, and expanding companion diagnostic approvals.

Regional Market Analysis
Market share and growth rate by region
Regional market analysis — market share, growth rate and largest market by region.
RegionMarket shareGrowth rateLargest market
North America45.0%9.5%United States
Europe30.0%8.2%Germany
Asia Pacific25.0%12.8%China

North America

#1
Share: 45.0%CAGR: 9.5%

Largest market: United States

Europe

#2
Share: 30.0%CAGR: 8.2%

Largest market: Germany

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
05

Market Dynamics

  • Rising prevalence of cancer and chronic diseases requiring personalized treatment
  • Advances in genomic sequencing reducing per-test costs significantly
  • Increased FDA approvals for companion diagnostics and targeted therapies
06

Market Segmentation

By Technology
Market share distribution across 5 segments
By Technology — market share by segment, in percent.
SegmentShare
Genomics / Next-Generation SequencingLargest technology segment driven by declining sequencing costs and expanding clinical applications.35.0%
BioinformaticsCritical for analyzing complex genomic data and enabling AI-driven biomarker discovery.20.0%
Companion DiagnosticsGrowing alongside targeted therapies with increasing FDA CDx approvals.20.0%
Targeted TherapiesSmall-molecule inhibitors and biologics designed for genetically defined patient populations.15.0%
Gene TherapyEmerging segment with CRISPR and viral vector-based treatments gaining clinical traction.10.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
By Application
Market share distribution across 6 segments
By Application — market share by segment, in percent.
SegmentShare
OncologyLargest application area with extensive use of genomic profiling for treatment selection.45.0%
Cardiovascular DiseasesPharmacogenomics guiding anticoagulant and antiplatelet therapy decisions.15.0%
Neurological DisordersGenetic testing for Alzheimer's, Parkinson's, and rare neurological conditions.12.0%
Rare DiseasesWhole-exome and genome sequencing enabling diagnosis of previously undiagnosed conditions.10.0%
Infectious DiseasesPathogen genomics and host-response profiling for personalized antimicrobial therapy.8.0%
OthersIncludes immunology, metabolic disorders, and reproductive health applications.10.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.

By End User

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutes
  • Pharmaceutical Companies
07

Regional Analysis

1

North America

Lead: United States
CAGR: 9.5%Share: 45.0%

Largest regional market driven by advanced healthcare infrastructure, strong R&D funding, and favorable regulatory environment.

2

Europe

Lead: Germany
CAGR: 8.2%Share: 30.0%

Second-largest market supported by growing genomic initiatives and increasing adoption of companion diagnostics.

3

Asia Pacific

Lead: China
CAGR: 12.8%Share: 25.0%

Fastest-growing region fueled by rising healthcare expenditure, expanding genomics infrastructure, and large patient populations.

Country-Level Analysis

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Market share and growth rate by country
CountryShareGrowth
United States
42.0%
+9.5%
Germany
10.0%
+8.0%
China
12.0%
+14.2%
08

Competitive Landscape

R

Roche Diagnostics

Switzerland

Leader68B

Dominates companion diagnostics and oncology precision medicine through Foundation Medicine and extensive CDx portfolio.

Global leader in companion diagnostics and oncology precision medicine, leveraging Foundation Medicine's comprehensive genomic profiling platforms.

T

Thermo Fisher Scientific

United States

Challenger220B

Largest consumables and reagents provider; expanded into proteomics with Olink Proteomics acquisition in 2024.

World's largest provider of scientific instruments and reagents for genomic analysis, with expanding proteomics capabilities through Olink acquisition.

I

Illumina, Inc.

United States

Follower4.8B

Leading NGS platform provider serving millions of patients globally with comprehensive genomic sequencing solutions.

Dominant next-generation sequencing platform provider enabling large-scale genomic testing across research and clinical diagnostics worldwide.

09

Recent Developments

25
2025Roche Diagnostics

Expanded Foundation Medicine liquid biopsy capabilities with new circulating tumor DNA panels for real-time treatment monitoring.

24
2024Thermo Fisher Scientific

Completed acquisition of Olink Proteomics to integrate protein-level data with genomic insights for comprehensive precision medicine solutions.

10

Regulatory Landscape

FDA's continued expansion of Companion Diagnostic approvals under the In Vitro Diagnostic framework21st Century Cures Act provisions accelerating precision medicine device clearances
11

Research Methodology

Primary research

  • Expert interviews
  • Surveys

Secondary research

  • Industry reports
  • Company financials

Validation: Triangulation method

12

Strategic Takeaways

Investors

The US precision medicine market offers strong growth potential with a 9.5% CAGR, driven by oncology genomics and AI-enabled diagnostics.

Operators

Invest in NGS infrastructure, bioinformatics capabilities, and companion diagnostics to capture growing demand across hospitals and research institutes.

13

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.